Good day and thank you for joining us.
Good day, Mr. Clark. This framework legislation was enacted in 2004, but there is still no pharmaceutical manufacturing capacity in developing countries. I'm trying to understand the reasons for this state of affairs. Regarding the WTO's terms and conditions for waiving certain obligations, you note the following in your document: “Licensees must pay adequate remuneration to the patentee(s)”.
What exactly do you mean by that? Is this the sticking point?
You go on to say this: “Waiver must be used in “good faith” and not for commercial or industrial objectives.”
Can you tell us what you mean by “adequate remuneration”? I'd also like to know if it is easy to obtain a waiver in good faith?